References of "Evrard, Brigitte"
     in
Bookmark and Share    
Peer Reviewed
See detailMulti-biomaterial for controlled release of active substances
Zalfen, Alina; Nizet, Dominique; Jérôme, Christine ULg et al

Poster (2006)

Detailed reference viewed: 16 (0 ULg)
Peer Reviewed
See detailEffect of cyclodextrins on the membrane permeability of liposomes
Piel, Géraldine ULg; Piette, Marie ULg; Barillaro, Valery et al

Poster (2005, November)

Detailed reference viewed: 41 (3 ULg)
Full Text
Peer Reviewed
See detailAutomated method for the determination of a new matrix metalloproteinase inhibitor in ovine plasma and serum by coupling of restricted access material for on-line sample clean-up to liquid chromatography
Chiap, Patrice ULg; Piette, Marie ULg; Evrard, Brigitte ULg et al

in Journal of Chromatography. B : Analytical Technologies in the Biomedical & Life Sciences (2005), 817(1), 109-117

A fully automated liquid chromatographic method was developed for the determination of Ro 28-2653, a new synthetic inhibitor of matrix metalloproteinases (MMPs), in ovine serum and plasma. The method was ... [more ▼]

A fully automated liquid chromatographic method was developed for the determination of Ro 28-2653, a new synthetic inhibitor of matrix metalloproteinases (MMPs), in ovine serum and plasma. The method was based on the coupling of a pre-column packed with restricted access material, namely LiChrospher RP-8 ADS (alkyl diol silica), for sample clean-up to an analytical column containing octyl silica stationary phase. One hundred mul of biological sample, to which 2-propanol was automatically added, were injected onto the ADS pre-column, which was then washed with a washing liquid consisting of a mixture of 25 mM phosphate buffer (pH 7.0) and acetonitrile (90: 10; v/v) for 10 min. By rotation of the switching valve, the analyte was then eluted in the back-flush mode with the LC mobile phase composed of a mixture of acetonitrile and 25 mM phosphate buffer (pH 7.0) (57:43; v/v). The UV detection was performed at 395 nm. The main parameters likely to influence the sample preparation technique were investigated. The method was then validated over a concentration range from 17.5 to 1950 ng/mI, the first concentration level corresponding to the lower limit of quantitation. At this concentration level, the mean bias and the R.S.D. value for intermediate precision were -2.4% and 4.2%, respectively. (C) 2004 Elsevier B.V. All rights reserved. [less ▲]

Detailed reference viewed: 70 (19 ULg)
Full Text
Peer Reviewed
See detailSolid Lipid Microparticles: Formulation, Preparation, Characterisation, Drug Release and Applications
Jaspart, Séverine ULg; Piel, Géraldine ULg; Delattre, Luc ULg et al

in Expert Opinion on Drug Delivery (2005), 2(1), 75-87

This review details the properties of solid lipid microparticles (SLMs): a promising drug carrier system that has been until now rather unexploited. First, the advantages of SLMs compared with other drug ... [more ▼]

This review details the properties of solid lipid microparticles (SLMs): a promising drug carrier system that has been until now rather unexploited. First, the advantages of SLMs compared with other drug carrier systems are listed. Then an overview of SLM manufacturing compounds and techniques is presented. A detailed discussion of the characteristics of SLMs follows, and includes the determination of particle size distribution, the determination of SLM morphology, the solid-state analysis, the determination of SLM drug loading and the factors influencing it. The in vitro drug release studies that have been carried out so far and the parameters affecting them are also described. Some preliminary in vivo aspects (in vivo drug release studies, biocompatibility studies and in vivo fate) are also considered. [less ▲]

Detailed reference viewed: 64 (4 ULg)
Peer Reviewed
See detailIn vitro release of salbutamol acetonide from solid lipid nanoparticles
Jaspart, Séverine ULg; Bodson, Cédric; Bertholet, Pascal et al

in Proceedings of 1st Pharmaceutical Sciences Fair and Exhibition (2005)

Detailed reference viewed: 34 (1 ULg)
Peer Reviewed
See detailEvaluation of the pulmonary inflammation and bronchial hyperresponsiveness in healthy mice induced by inhaled cyclodextrins
Guéders, Maud ULg; Bertholet, P.; Barillaro, Valery et al

in Journal of inclusion Phenomena and Macrocyclic Chesmistry (2005)

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailOral bioavailability in pigs of a miconazole/hydroxypropyl-gamma-cyclodextrin/L-tartaric acid inclusion complex produced by supercritical carbon dioxide processing
Barillaro, Valery; Evrard, Brigitte ULg; Delattre, Luc ULg et al

in AAPS Journal (2005), 7(1), 149-155

The objective of this study was to determine the pharmacokinetic parameters of miconazole after oral administration of a miconazole/hydroxypropyl-gamma-cyclodextrin(HPgammaCD)/L-tartaric acid inclusion ... [more ▼]

The objective of this study was to determine the pharmacokinetic parameters of miconazole after oral administration of a miconazole/hydroxypropyl-gamma-cyclodextrin(HPgammaCD)/L-tartaric acid inclusion complex produced by supercritical carbon dioxide processing. The pharmacokinetics of the miconazole ternary complex (CPLX), of the corresponding physical mixture (PHYS), and of miconazole alone (MICO) were compared after oral administration. Six mixed-breed pigs received each formulation as a single dose (10 mg miconazole/kg) in a crossover design. Miconazole plasma concentrations were determined by a high-performance liquid chromatography method. Preliminary in vitro dissolution data showed that CPLX exhibits a faster and higher dissolution rate than either PHYS or MICO. Following CPLX oral administration, mean area under the plasma concentration curve (AUC(0-infinity)) for miconazole was 95.0 +/- 55.8 microg/min/mL, with the peak plasma concentration (C(max) 0.59 +/- 0.39 microg/mL) at 19.30 minutes. The AUC(0-infinity) and C(max) values were significantly higher than those after oral administration of PHYS (AUC(0-infinity) 38.5 +/- 12.7 microg/min/mL and C(max) 0.24 +/- 0.08 microg/mL; P < .1) and of MICO (AUC(0-infinity) 24.1 +/- 14.0 microg/min/mL and C(max) 0.1 +/- 0.05 microg/mL; P < .1). There were also significant differences between PHYS and MICO (P < .1). The results of the study indicate that CPLX shows improved dissolution properties and a higher relative oral bioavailability compared with PHYS and MICO. [less ▲]

Detailed reference viewed: 56 (3 ULg)
Peer Reviewed
See detailComparison of bronchodilators in feline airways: In vitro and in vivo investigations
Leemans, Jérôme ULg; Kirschvink, Nathalie; Delvaux, F. et al

in In proceedings: 15th Congress European College of Veterinary Internal Medicine – companion animals (2005)

Detailed reference viewed: 19 (3 ULg)
Peer Reviewed
See detailEvaluation of the bronchoprotective effects of inhaled salmeterol, fenoterol and oxitropium in healthy cats
Kirschvink, Nathalie; Leemans, Jérôme ULg; Delvaux, F. et al

in Fundamental & Clinical Pharmacology (2005), 19

Detailed reference viewed: 24 (1 ULg)
Peer Reviewed
See detailIn vitro and in vivo effects of salbutamol acetonide on cat airways
Leemans, Jérôme ULg; Kirschvink, Nathalie; Delvaux, F. et al

in Proceedings: Société Belge de Physiologie et de Pharmacologie Fondamentales et Cliniques (2005)

Detailed reference viewed: 18 (3 ULg)
Peer Reviewed
See detailIn vitro pharmacological activity of salbutamol acetonide on the isolated guinea-pig trachea and porcine bronchus
Leemans, Jérôme ULg; Kirschvink, Nathalie; Delvaux, F. et al

in Fundamental & Clinical Pharmacology (2005), 19

Detailed reference viewed: 21 (6 ULg)
Full Text
Peer Reviewed
See detailThe Effect of Cyclodextrins on the Aqueous Solubility of a New Mmp Inhibitor: Phase Solubility, 1 H-Nmr Spectroscopy and Molecular Modeling Studies, Preparation and Stability Study of Nebulizable Solutions
Bertholet, Pascal; Guéders, Maud ULg; Dive, Georges ULg et al

in Journal of Pharmacy & Pharmaceutical Sciences : A Publication of the Canadian Society for Pharmaceutical Sciences (2005), 8(2), 164-175

PURPOSE: Ro 28-2653 (RO) is a synthetic inhibitor of matrix metalloproteinases (MMPs), which is potentially effective against bronchial remodeling. Given that this molecule has very poor aqueous ... [more ▼]

PURPOSE: Ro 28-2653 (RO) is a synthetic inhibitor of matrix metalloproteinases (MMPs), which is potentially effective against bronchial remodeling. Given that this molecule has very poor aqueous solubility, different cyclodextrins (CDs) have been tested to increase its solubility. The aim of this study was to prepare and to characterize inclusion complexes between RO and CDs, in order to develop nebulizable solutions. METHODS: The complex formation was investigated by phase solubility studies. (1)H-NMR spectroscopy and molecular modeling studies were carried out to elucidate the structure of the inclusion complex between RO and dimethyl-beta-CD (DIMEB). Nebulizable solutions of RO were developed with CDs and a stability study was performed over 9 months. RESULTS: The phase solubility studies showed that beta-CD and its derivatives form a 1:2 complex with RO, whereas gamma-CD includes RO with a 1:1 stoichiometry and a weak stability constant. T-ROESY spectra showed that DIMEB is able to complex two RO substituents (nitrophenyl and biphenyl groups) with preferential orientations, while molecular modeling demonstrated that the configurations observed with (1)H-NMR are energetically favorable, especially owing to H-bond formation between RO and DIMEB. Two CDs were selected to develop nebulizable solutions of RO and the stability study demonstrated that RO degradation in solution is strongly dependent on the concentration of the 1:2 inclusion complex. CONCLUSIONS: CDs are able to include RO and to improve its aqueous solubility. The beta-CD derivatives can be used to formulate nebulizable solutions of RO, the stability of which depends on the concentration of the 1:2 complex. [less ▲]

Detailed reference viewed: 45 (14 ULg)